Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 2-Part Study (Open-label Followed by Double-blind, Randomized, Placebo-controlled, Parallel Group) of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode

Trial Profile

A 2-Part Study (Open-label Followed by Double-blind, Randomized, Placebo-controlled, Parallel Group) of the Safety, Tolerability, Pharmacokinetics, and Efficacy of SAGE-217 in the Treatment of Subjects With Bipolar I/II Disorder With a Current Major Depressive Episode

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs SAGE 217 (Primary)
  • Indications Bipolar depression; Major depressive disorder
  • Focus Adverse reactions
  • Acronyms ARCHWAY
  • Sponsors Sage Therapeutics
  • Most Recent Events

    • 07 Jan 2019 According to a SAGE Therapeutics media release, results from the part A open-label portion this ARCHWAY study is expected 1H 2019.
    • 18 Oct 2018 Status changed from active, no longer recruiting to recruiting.
    • 09 Oct 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top